US005753656A

United States Patent [19]

Sakai et al.

[11] Patent Number: 5,753,656

[45] Date of Patent: May 19, 1998

[54] **METHOD FOR TREATING SPINOCEREBELLAR DEGENERATION**

[75] Inventors: **Tetsuo Sakai**; **Yasunobu Antoku**; **Toyojiro Matsuishi**, all of Fukuoka-ken, Japan

[73] Assignee: **Suntory Limited**, Osaka, Japan

[21] Appl. No.: **632,412**

[22] PCT Filed: **Aug. 4, 1995**

[86] PCT No.: **PCT/JP95/01550**

§ 371 Date: **Apr. 3, 1996**

§ 102(e) Date: **Apr. 3, 1996**

[87] PCT Pub. No.: **WO96/03989**

PCT Pub. Date: **Feb. 15, 1996**

[30] **Foreign Application Priority Data**

Aug. 5, 1994 [JP] Japan 6-184682

[51] **Int. Cl.**[6] **A61K 31/495**

[52] **U.S. Cl.** **514/249**

[58] **Field of Search** 514/249

[56] **References Cited**

U.S. PATENT DOCUMENTS

4,774,244	9/1988	Curtius et al.	514/249
4,920,122	4/1990	Naruse et al.	514/254

FOREIGN PATENT DOCUMENTS

59-25323	2/1984	Japan .
59-76086	4/1984	Japan .
61-277618	12/1986	Japan .
63-267781	11/1988	Japan .
9310155	5/1993	WIPO .

OTHER PUBLICATIONS

J. Pharmacol. Exp. Ther., 242(2), pp. 514–522, 1987.

Research Report by Medical Application Research Foundation, 12, pp. 233–240, 1994.

Sakai, Tetsuo, *Clinical Characteristics of Joseph Disease. A proposal of diagnostic criteria.*; 1989, pp. 216–252.

Mello, Karen et al., *Effects of Sulfamethoxazole and Trimethoprim on Neurologic Dysfunction in a Patient With Joseph's Disease*, Arch. Neurol., vol. 45, Feb. 1988, pp. 210–213.

Primary Examiner—Raymond Henley, III

Attorney, Agent, or Firm—Cushman Darby & Cushman IP Group of Pillsbury Madison & Sutro LLP

[57] **ABSTRACT**

The object of the present invention is to provide a therapeutic agent which effectively ameliorates neurologic symptoms in spinocerebellar degeneration. The present invention provides a therapeutic agent for spinocerebellar degeneration comprising as an effective ingredient a compound represented by the formula:



[wherein R^1 and R^2 each represents a hydrogen atom or, together, represent a single bond while R^3 represents —CH(OH)CH(OH)CH_3, —CH(OCOCH_3)CH(OCOCH_3)CH_3, —CH_3, —CH_2OH or a phenyl group when R^1 and R^2 each represents a hydrogen atom, or —COCH(OH)CH_3 when R^1 and R^2 together represent a single bond] or its pharmaceutically acceptable salt.

5 Claims, No Drawings